Kengo Nagashima

研究業績

Paper(s) Under Review

  1. Noma H, Nagashima K, Kato S, Teramukai S, Furukawa TA. Flexible random-effects distribution models for meta-analysis. Under review. [arXiv:2003.04598]
  2. Hamaguchi Y, Noma H, Nagashima K, Yamada T, Furukawa TA. Frequentist performances of Bayesian prediction intervals for random-effects meta-analysis. Under review. [arXiv:1907.00345]
  3. Nagashima K, Noma H, Furukawa TA. pimeta: an R package of prediction intervals for random-effects meta-analysis. Under review.
  4. Nagashima K, Noma H, Sato Y, Gosho M. Sample size calculations for single-arm survival studies using transformations of the Kaplan–Meier estimator. Under review.

Publications (Peer-Reviewed)

    Statistical Methodology

  1. Noma H, Nagashima K, Furukawa TA. Permutation inference methods for multivariate meta-analysis. Biometrics 2020;76(1):337–347. DOI: 10.1111/biom.13134. [arXiv:1809.03935]
  2. Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a confidence distribution approach. Statistical Methods in Medical Research 2019;28(6):1689–1702. DOI: 10.1177/0962280218773520. [arXiv:1804.01054] [Software]
  3. Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA. Bartlett-type corrections and bootstrap adjustments of likelihood-based inference methods for network meta-analysis. Statistics in Medicine 2018;37(7):1178–1190. DOI: 10.1002/sim.7578.
  4. Nagashima K, Sato Y. Information criteria for Firth's penalized partial likelihood approach in Cox regression models. Statistics in Medicine 2017;36(21):3422–3436. DOI: 10.1002/sim.7368. [Postprint] Open access
  5. Noma H, Nagashima K. A note on the Mantel–Haenszel estimators when the common effect assumptions are violated. Epidemiologic Methods 2016;5(1):19–35. DOI: 10.1515/em-2015-0004. Free access
  6. Nagashima K, Sato Y, Noma H, Hamada C. An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach. Statistics in Medicine 2013;32(27):4838–4858. DOI: 10.1002/sim.5895. [arXiv:1805.05017]
  7. Nagashima K, Sato Y, Hamada C. A modified maximum contrast method for unequal sample sizes in pharmacogenomic studies. Statistical Applications in Genetics and Molecular Biology 2011;10(1):Article 41. DOI: 10.2202/1544-6115.1560. [Postprint] [Software]
  8. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada J-i, Yoshida T. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. The Pharmacogenomics Journal 2009;9(2):137–146. DOI: 10.1038/tpj.2008.17. Free access

    9. Applications and Reviews in Biostatistics

  9. Gosho M, Sato Y, Nagashima K, Takahashi S. Trends in study design and the statistical methods employed in a leading general medicine journal. Journal of Clinical Pharmacy and Therapeutics 2018;43(1):36–44. DOI: 10.1111/jcpt.12605.
  10. Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM. Statistical methods in the Journal — an update. New England Journal of Medicine 2017;376(11):1086–1087. DOI: 10.1056/NEJMc1616211. (Correspondence) HOT
  11. Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research. Sensors 2012;12(7):8966–8986. DOI: 10.3390/s120708966. (Review) Open access

    12. Medical Researches

  12. Katsumata Y, Terada J, Matsumura T, Koshikawa K, Sakao S, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda H, Nagashima K, Kobayashi Y, Kobayashi E, Iwadate Y, Zhang X-M, Hiwasa T, Tatsumi K. Circulating anti-sorting nexins 16 antibodies as an emerging biomarker of coronary artery disease in patients with obstructive sleep apnea. Diagnostics 2020;10(2):71. DOI: 10.3390/diagnostics10020071. Open access
  13. Suichi T, Misawa S, Nagashima K, Sato Y, Iwai Y, Katayama K, Sekiguchi Y, Shibuya K, Amino H, Suzuki Y-i, Tsuneyama A, Nakamura K, Kuwabara S. Lenalidomide treatment for thalidomide-refractory POEMS syndrome: A prospective single-arm clinical trial. Internal Medicine 2020. In press. DOI: 10.2169/internalmedicine.3800-19. Open access
  14. Ishikawa M, Iwasa S, Aoki M, Imazeki H, Hirano H, Shoji H, Honma Y, Okita N, Nagashima K, Takashima A, Kato K, Saruta M, Boku N. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. Investigational New Drugs 2020;38(2):533–540. DOI: 10.1007/s10637-019-00822-3.
  15. Iwase T, Sangai T, Fujimoto H, Sawabe Y, Matsushita K, Nagashima K, Sato Y, Nakagawa A, Masuda T, Nagashima T, Ohtsuka M. Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer. Breast Cancer Research and Treatment 2020;179(2):435–443. DOI: 10.1007/s10549-019-05467-7.
  16. Satomi NT, Honma Y, Nagashima K, Umezawa R, Ito Y, Hirano H, Shoji H, Takashima A, Iwasa S, Kato K, Hamaguchi T, Itami J, Boku N. Risk factors of severe benign cicatricial stricture after definitive chemoradiation for localized T3 esophageal carcinoma. Anticancer Research 2020;40(2):1071–1077. DOI: 10.21873/anticanres.14045.
  17. Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer Medicine 2020;9(2):595–604. DOI: 10.1002/cam4.2708. Open access
  18. Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A. Hand-held flow meter improves COPD detectability regardless of using a conventional questionnaire: a split-sample validation study. Respirology 2020;25(2):191–197. DOI: 10.1111/resp.13602.
  19. Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T, Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hihara J, Sakamoto T, Fukagawa T, Katai H, Higuchi K, Boku N. Efficacy of post-operative chemotherapy after resection leaving no macroscopically visible disease of gastric cancer with peritoneal lavage cytology positive (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study. Annals of Surgical Oncology 2020;27(1):284–292. DOI: 10.1245/s10434-019-07697-x.
  20. Nomura K, Nagashima K, Suzuki T, Itoh H. Application of Japanese guidelines for gestational weight gain to multiple pregnancy outcomes and its optimal range in 101,336 Japanese women. Scientific Reports 2019;9(1):17310. DOI: 10.1038/s41598-019-53809-8. Open access
  21. Masuda K, Shoji H, Nagashima K, Yamamoto S, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 2019;19(1):974. DOI: 10.1186/s12885-019-6150-y. Open access
  22. Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy. Cancer Medicine 2019;8(15):6566–6577. DOI: 10.1002/cam4.2502. Open access
  23. Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Scientific Reports 2019;9(1):12071. DOI: 10.1038/s41598-019-48600-8. Open access
  24. Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N, Nagashima K, Ito Y, Itami J. Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Esophagus 2019;16(4):402–407. DOI: 10.1007/s10388-019-00680-1.
  25. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, On behalf of the PRIME-V study group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study). Diabetes, Obesity and Metabolism 2019;21(8):1990–1995. DOI: 10.1111/dom.13750. Open access
  26. Fujita M, Nagashima K, Takahashi S, Hata A. Inequality within a community at the neighborhood level and the incidence of mood disorders in Japan: a multilevel analysis. Social Psychiatry and Psychiatric Epidemiology 2019;54(9):1125–1131. DOI: 10.1007/s00127-019-01687-w.
  27. Aoki M, Shoji H, Nagashima K, Imazeki H, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Higuchi K, Boku N. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open 2019;4:e000488. DOI: 10.1136/esmoopen-2019-000488. Open access
  28. Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S, Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Design, Development and Therapy 2019;13:809–816. DOI: 10.2147/DDDT.S197237. Open access
  29. Hiramoto S, Tamaki T, Nagashima K, Hori T, Kikuchi A, Yoshioka A, Inoue A. Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer. International Journal of Clinical Oncology 2019;24(4):454–459. DOI: 10.1007/s10147-018-1363-7.
  30. Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Nagashima K, Igaki H. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. International Journal of Clinical Oncology 2019;24(1):60–67. DOI: 10.1007/s10147-018-1336-x.
  31. Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y. Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. British Journal of Radiology 2018;91(1089):20180259. DOI: 10.1259/bjr.20180259. Free access
  32. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Medical costs attributable to overweight and obesity in Japanese individuals. Obesity Research & Clinical Practices 2018;12(5):479–484. DOI: 10.1016/j.orcp.2018.06.002.
  33. Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Nagashima K, Hanaoka H, Kobayashi Y. Intravenous nicorandil versus adenosine for fractional flow reserve measurement: A crossover, randomized study. Heart and Vessels 2018;33(12):1570–1575. DOI: 10.1007/s00380-018-1197-2.
  34. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K-i, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, for the Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519–529. DOI: 10.1016/S1474-4422(18)30114-5. HOT
  35. Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizogami M, Hata A. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. Journal of Viral Hepatitis 2018;25(11):1312–1320. DOI: 10.1111/jvh.12933.
  36. Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, Sakao S, Nagashima K, Ozaki T, Kobayashi Y, Hiwasa T, Tatsumi K. Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): a potential biomarker for coronary artery disease in patients with obstructive sleep apnea. PLoS ONE 2018;13(3):e0195015. DOI: 10.1371/journal.pone.0195015. Open access
  37. Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K. Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. International Journal of Clinical Oncology 2018;23(4):652–658. DOI: 10.1007/s10147-018-1258-7.
  38. Watanabe K, Hirano S, Kojima K, Nagashima K, Mukai H, Sato T, Takemoto M, Matsumoto K, Iimori T, Isose S, Omori S, Shibuya K, Sekiguchi Y, Beppu M, Amino H, Suichi T, Yokote K, Uno T, Kuwabara S, Misawa S. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Journal of Neurology, Neurosurgery, and Psychiatry 2018;89(10):1082–1087. DOI: 10.1136/jnnp-2017-316601.
  39. Kotooka N, Kitakaze M, Nagashima K, Asaka M, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D, Yamada Y, Kuratomi A, Okada N, Fujimatsu D, Kuwahata S, Toyoda S, Hirotani S-i, Komori T, Eguchi K, Kario K, Inomata T, Sugi K, Yamamoto K, Tsutsui H, Masuyama T, Shimokawa H, Momomura S-i, Seino Y, Sato Y, Inoue T, Node K, On behalf of the HOMES-HF study investigators. The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF). Heart and Vessels 2018;33(8):866–876. DOI: 10.1007/s00380-018-1133-5.
  40. Inagaki T, Terada J, Yahaba M, Kawata N, Jujo T, Nagashima K, Sakao S, Tanabe N, Tatsumi K. Heart rate and oxygen saturation change patterns during a 6-min walk test in subjects with chronic thromboembolic pulmonary hypertension. Respiratory Care 2018;63(5):573–583. DOI: 10.4187/respcare.05788. Free access
  41. Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. Gastric Cancer 2018;21(3):439–445. DOI: 10.1007/s10120-017-0753-2.
  42. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. International Journal of Clinical Oncology 2018;23(2):382–388. DOI: 10.1007/s10147-017-1200-4.
  43. Kinoshita T, Yahaba M, Terada J, Matsumura T, Sakurai Y, Sakao S, Nagashima K, Tatsumi K. Impact of arterial stiffness on Watch-PAT variables in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine 2018;14(3):319–325. DOI: 10.5664/jcsm.6970. Free access
  44. Korematsu S, Nagashima K, Sato Y, Nagao M, Hasegawa S, Nakamura H, Sugiura S, Miura K, Okada K, Fujisawa T. "Spike" in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A nation-wide survey. Allergology International 2018;67(1):55–60. DOI: 10.1016/j.alit.2017.04.003. Open access
  45. Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D, Nagashima K, Boku N. Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Cancer Chemotherapy and Pharmacology 2017;80(3):575–582. DOI: 10.1007/s00280-017-3397-3.
  46. Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, Watabe Y, Watanabe S-i, Noro R, Nagashima K, Huang W, Yamada T, Asamura H, Ohe Y, Honda K. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomarkers in Medicine 2017;11(9):721–731. DOI: 10.2217/bmm-2017-0150. Open access
  47. Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y. Clinical outcomes of resectable esophageal cancer with supraclavicular lymph node metastases treated with curative intent. Anticancer Research 2017;37(7):3741–3749. DOI: 10.21873/anticanres.11748.
  48. Nishide A, Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income-related inequalities in access to dental care services in Japan. International Journal of Environmental Research and Public Health 2017;14(5):524. DOI: 10.3390/ijerph14050524. Open access
  49. Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Hamaguchi T. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget 2017;8(56):95083–95094. DOI: 10.18632/oncotarget.18297. Open access
  50. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Impact of geographic accessibility on utilization of the annual health check-ups by income level in Japan: A multilevel analysis. PLoS ONE 2017;12(5):e0177091. DOI: 10.1371/journal.pone.0177091. Open access
  51. Nomura K, Kido M, Tanabe A, Nagashima K, Takenoshita S, Ando K. Investigation of optimal weight gain during pregnancy for Japanese Women. Scientific Reports 2017;7(1):2569. DOI: 10.1038/s41598-017-02863-1. Open access
  52. Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K, Tatsumi K, Hiwasa T. Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential biomarker for cardio- and cerebro-vascular events in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine 2017;13(3):393–400. DOI: 10.5664/jcsm.6488. Free access
  53. Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimousa R, Takahashi S, Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K, on behalf of the PRIME-V Study Investigators. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in type 2 diabetes patients receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: A study protocol for a prospective, multicenter, blinded-endpoint phase IV randomized controlled trial (PRIME-V study). BMJ Open 2017;7(5):e015766. DOI: 10.1136/bmjopen-2016-015766. Open access
  54. Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 2017;20(4):655–662. DOI: 10.1007/s10120-016-0670-9.
  55. Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima K, Takahashi K. Quantitative US elastography can quantify mechanical and histological tendon healing in a rabbit model of achilles tendon transection. Radiology 2017;283(2):408–417. DOI: 10.1148/radiol.2016160695. Free access
  56. Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida K-I, Suzuki N, Nodera H, Tsuji S, Koike H, Kira J-I, Hanaoka H, Kusunoki S, Kuwabara S, JET-GBS Group. A prospective, multi-center, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barré syndrome (GBS): Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols 2016;5(4):e210. DOI: 10.2196/resprot.6610. Open access
  57. Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Nagashima K, Hanaoka H, Kobayashi Y. Efficacy of intravenous nicorandil for fractional flow reserve assessment: Study protocol for a crossover randomised trial. BMJ Open 2016;6(11):e012737. DOI: 10.1136/bmjopen-2016-012737. Open access
  58. Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2016;15(11):1129–1137. DOI: 10.1016/S1474-4422(16)30157-0. HOT
  59. Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunology Research 2016;4(7):592–599. DOI: 10.1158/2326-6066.CIR-15-0298. Free access
  60. Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue M, Nagashima K, Yamada Y. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. Cancer Science 2016;107(7):1006–1012. DOI: 10.1111/cas.12950. Open access
  61. Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote K, Hanaoka H. Comparison of drug use between clinical practice and regulatory approval: results in older Japanese patients with rheumatoid arthritis, diabetes, high blood pressure, or depression. Therapeutic Innovation & Regulatory Science 2016;50(6):743–750. DOI: 10.1177/2168479016648731.
  62. Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Yamada Y, Shimada Y. Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan for KRAS wild-type metastatic colorectal cancer. Anticancer Research 2016;36(7):3531–3536. URL: http://ar.iiarjournals.org/content/36/7/3531. Free access
  63. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income related inequality of health care access in Japan: A retrospective cohort study. PLoS ONE 2016;11(3):e0151690. DOI: 10.1371/journal.pone.0151690. Open access
  64. Tawada A, Chiba T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Arai M, Kanda T, Shinozaki M, Goto N, Nagashima K, Yokosuka O. Utility of prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Oncology 2016;90(4):199–208. DOI: 10.1159/000444392.
  65. Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Nagashima K, Takahashi K. Quantitative ultrasound elastography with an acoustic coupler for achilles tendon elasticity: measurement repeatability and normative values. Journal of Ultrasound in Medicine 2016;35(1):159–166. DOI: 10.7863/ultra.14.11042. Free access
  66. Naito S, Tanaka J, Nagashima K, Chang B, Hishiki H, Takahashi Y, Oikawa J, Nagasawa K, Shimojo N, Ishiwada N. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan. Epidemiology and Infection 2016;144(3):494–506. DOI: 10.1017/S0950268815001272. Free access
  67. Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A, on behalf of the KAICA Trial investigators. Study protocol for a phase III multi-centre, randomized, open-label, blinded-endpoint trial to evaluate the efficacy and safety of immunoglobulin plus Cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open 2015;5(12):e009562. DOI: 10.1136/bmjopen-2015-009562. Open access
  68. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Validity assessment of self-reported medication use by comparing to pharmacy insurance claims. BMJ Open 2015;5(11):e009490. DOI: 10.1136/bmjopen-2015-009490. Open access
  69. Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita N, Shimada Y, Yamada Y. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. Cancer Chemotherapy and Pharmacology 2015;76(3):605–614. DOI: 10.1007/s00280-015-2834-4.
  70. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Predictive power of a body shape index for development of diabetes, hypertension, and dyslipidemia in Japanese adults: a retrospective cohort study. PLoS ONE 2015;10(6):e0128972. DOI: 10.1371/journal.pone.0128972. Open access
  71. Utsumi H, Honma Y, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Kishi Y, Nara S, Esaki M, Shimada K. Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer. Anticancer Research 2015;35(4):2255–2261. URL: http://ar.iiarjournals.org/content/35/4/2255. Free access
  72. Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Science 2015;106(5):604–610. DOI: 10.1111/cas.12642. Open access
  73. Nagashima K, Yanai T, Iwasa S, Ohyanagi F, Kasai T, Minato K, Sakai H, Sakamoto C, Takeda K, Harada D, Goto K, Yamamoto N. A double-blind randomized phase II study of olanzapine 10 mg versus 5 mg for highly emetogenic chemotherapy-induced emesis. Japanese Journal of Clinical Oncology 2015;75(2):229–231. DOI: 10.1093/jjco/hyu191. Free access
  74. Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology 2014;74(6):1207–1215. DOI: 10.1007/s00280-014-2597-3.
  75. Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima S, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Science 2014;105(8):1002–1007. DOI: 10.1111/cas.12453. Open access
  76. Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Research 2013;33(1):309–316. URL: http://ar.iiarjournals.org/content/33/1/309. Free access
  77. Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada Y. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. International Journal of Clinical Oncology 2012;17(6):604–609. DOI: 10.1007/s10147-011-0331-2.
  78. Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Investigational New Drugs 2012;30(5):2026–2031. DOI: 10.1007/s10637-011-9779-1.
  79. Fujie H, Niu K, Ohba M, Tomioka Y, Kitazawa H, Nagashima K, Ohrui T, Numasaki M. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. Inflammation 2012;35(3):1119–1131. DOI: 10.1007/s10753-011-9419-0.
  80. Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K. Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma. Cancer Science 2012;103(2):233–238. DOI: 10.1111/j.1349-7006.2011.02142.x. Open access
  81. Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H, Matsumura Y, Yamamoto S, Shimada Y. Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial. Journal of Oncology Practice 2011;7(3):148–153. DOI: 10.1200/JOP.2010.000106.
  82. Hashimoto K, Takashima A, Nagashima K, Okazaki S, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. Journal of Cancer Research and Clinical Oncology 2010;136(7):1059–1064. DOI: 10.1007/s00432-009-0752-8.

著書 (翻訳書)

  1. 平川晃弘，五所正彦（監訳），安藤英一，佐藤泰憲，高橋翔，竹内久郎，長島健悟，中水流嘉臣，野間久史，藤井陽介，松岡信篤，松永信人，丸尾和司，山田将之（訳）．臨床試験のための アダプティブデザイン．朝倉書店 2018. (Chow SC, Chang M. Adaptive Design Methods in Clinical Trials, Second Edition. CRC Press, 2012.) [Web Site]
  2. 五所正彦（監訳），佐藤泰憲，竹内久朗，長島健悟，中水流嘉臣，平川晃弘，松永信人，山田雅之（訳）．生存時間解析入門 原書第2版．東京大学出版会 2014. (Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data, 2nd. Editon. Wiley, 2008.) [Web Site]

原著論文 (和文)

  1. 菊地綾子, 平本秀二, 堀哲雄, 吉岡亮, 長島健悟. 終末期進行がん患者における長期入院の予測因子と終末期症状・治療との関連. Palliative Care Research 2018;13(4):335–340. DOI: 10.2512/jspm.13.335
  2. 大島新司, 間祐太朗, 長島健悟, 田中享, 佐野元彦, 太田昌一郎, 細谷治, 安野伸浩, 從二和彦. フェンタニル貼付剤の粘着性に関する検討―貼付試験と粘着性による評価―. 日本緩和医療薬学雑誌 2012;5:7–13.

総説・解説

  1. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学研究における生存時間データの統計解析. 日本小児アレルギー学会誌 2016;30(5):659–665. DOI: 10.3388/jspaci.30.659.
  2. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学研究における統計モデル解析. 日本小児アレルギー学会誌 2016;30(4):580–586. DOI: 10.3388/jspaci.30.580.
  3. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学研究における症例数設計. 日本小児アレルギー学会誌 2016;30(2):190–197. DOI: 10.3388/jspaci.30.190.
  4. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学データの統計解析I：推定と検定. 日本小児アレルギー学会誌 2015;29(5):718–723. DOI: 10.3388/jspaci.29.718.
  5. 佐藤泰憲, 長島健悟, 高橋翔. 疫学研究の計画：研究デザインとデータ解析. 日本小児アレルギー学会誌 2015;29(3):312–317. DOI: 10.3388/jspaci.29.312.
  6. 佐藤泰憲, 高橋翔, 長島健悟. 臨床試験の計画：試験デザインとデータ解析. 日本小児アレルギー学会誌 2015;29(2):214–221. DOI: 10.3388/jspaci.29.214.
  7. 五所正彦, 長島健悟, 佐藤泰憲. バイオマーカー探索的研究デザイン. 日本臨牀 2012;70(5):874–879.
  8. 佐藤泰憲, 長島健悟, 浜田知久馬. 個別化医療のための研究デザインと統計解析法. 臨床薬理 2010;41(6):291–300. DOI: 10.3999/jscpt.41.291.

競争的資金等

    生物統計学

  1. 変量効果モデルによるメタアナリシスにおけるモデル誤特定下での統計的推測. 日本学術振興会：科学研究費補助金 若手研究 19K20229. 2019年4月–2022年3月. (研究代表者)
  2. ネットワークメタアナリシスにおける統計的推測・予測・モデリングの方法論の開発. 日本学術振興会：科学研究費補助金 基盤研究（B）19H04074. 2019年4月–2022年3月. (研究分担者)
  3. レアイベントデータに対する統計的推測と臨床研究への応用. 日本学術振興会：科学研究費補助金 若手研究(B) 16K16014. 2016年4月–2019年3月. (研究代表者)

    4. 臨床研究

  4. 情報通信技術を活用した子宮頸がん予防のヘルスリテラシー向上に関する研究. 日本学術振興会：科学研究費補助金 挑戦的研究（萌芽） 19K22737. 2019年7月–2022年3月. (研究分担者)
  5. 血液バイオマーカーを用いた効率的な膵がん検診の実用化. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2018年12月–2020年3月. (研究分担者)
  6. 非小細胞肺がんの転移活性を評価し、術後補助化学療法の効果を予測するバイオマーカーの実用化に関する研究. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2017年4月–2020年3月. (研究分担者)
  7. タンパク質・ペプチド修飾解析による早期がん・リスク疾患診断のための血液バイオマーカーの開発. 国立研究開発法人 日本医療研究開発機構：次世代がん医療創生研究事業. 2017年4月–2022年3月. (研究分担者)
  8. 性差に基づく薬物療法の有効性・安全性の評価研究. 国立研究開発法人 日本医療研究開発機構：女性の健康の包括的支援実用化研究事業—Wise. 2016年11月–2019年3月. (研究分担者)
  9. 膵がん検診の効率化を目指した血液バイオマーカーの実用化研究. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2016年9月–2017年3月. (研究分担者)

教育歴

講義

単発の講義

学会発表

Talks

    Statistical Methodology

  1. Noma H, Nagashima K. Improved Monte Carlo inference methods for network meta-analysis. The 12th International Conference of the ERCIM WG on Computational and Methodological Statistics (CMStatistics 2019), Dec. 15, 2019, London, UK. (Poster) [Abstract]
  2. Hamaguchi Y, Noma H, Nagashima K. Frequentist performances of the Bayesian prediction intervals for random effects meta-analysis. 40th Annual Conference of the International Society for Clinical Biostatistics (ISCB 40), Jul. 14–18, 2019, Leuven, Belgium. (Poster)
  3. Noma H, Nagashima K. Asymptotic behaviors of the Mantel–Haenszel estimators and their robust variance estimators when the common effect assumptions are violated. ENAR 2016 Spring Meeting, Mar. 6–9, 2016; JW Marriott Austin, Texas. (Poster) [Abstract]
  4. Noma H, Nagashima K. Asymptotic behaviors of the Mantel–Haenszel estimators under the common effect assumptions violated. Kyoto International Conference on Modern Statistics in the 21st Century, Nov. 17–18, 2014; Kyoto International Conference Center, Kyoto.
  5. Nagashima K, Sato Y. Information criterion for Firth-type penalized partial likelihood in Cox regression. The 27th International Biometric Conference, Jul. 6–11, 2014; Firenze Fiera, Italy. (Poster) [Abstract]
  6. Nagashima K, Sato Y, Hamada C. A high-speed method for population pharmacokinetic data analysis in genome-wide pharmacogenomic studies. The 26th International Biometric Conference, Aug. 26–31, 2012; Kobe Internatioanl Conference Center Kobe, Japan. (Poster) [Abstract]
  7. Nagashima K, Sato Y, Hamada C. Studentized modified maximum contrast method for unequal sample sizes in pharmacogenomics studies. The 25th International Biometric Conference, Dec. 5-10, 2010; Federal University of Santa Catarina, Florianópolis, SC, Brazil. [Abstract]
  8. Sato Y, Laird NM, Kato R, Nagashima K, Hamada C, Yoshimura I, Sakamoto H, Yoshida T. Modified maximum contrast method to detect pharmacokinetics-related genes in pharmacogenomics studies. 28th Annual Conference of the International Society for Clinical Biostatistics (ISCB 28), Aug. 2, 2007, Alexandroupolis, Greece.

    9. Medical Researches

  9. Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T, Michinoku Japan Urological Cancer Study Group. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer. ASCO 2020 Genitourinary Cancers Symposium, Feb. 13–15, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  10. Suzuki T, Aoki M, Shirasu H, Takahashi N, Nakatsuka R, Ando T, Kito Y, Yamamoto Y, Kawakami K, Matsumoto T, Shimozaki K, Nagase M, Yamaguchi T, Negoro Y, Tamura T, Amanuma Y, Esaki T, Miura Y, Nagashima K, Boku N. Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer: multicenter retrospective study in Japan. ASCO 2020 Gastrointestinal Cancers Symposium, Jan. 23–25, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  11. Nakayama I, Shoji H, Hara H, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Takahari D, Miyamoto T, Boku N, Kato K. Correlation of tumor mutation with efficacy in patients with gastric cancer who received nivolumab and ramucirumab combination therapy. ASCO 2020 Gastrointestinal Cancers Symposium, Jan. 23–25, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  12. Honda K, Kobayashi T, Sato Y, Nishiumi S, Okaya S, Takeuchi K, Nagashima K, Yoshida M. Stratification of pancreatic cancer risk in the general population using an apolipoprotein A2 isoform blood test. 50th Anniversary Meeting American Pancreatic Association & Japan Pancreas Society, Nov. 7, 2019, Maui, Hawaii. (Poster) [Abstract]
  13. Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Kitagawa K. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma. ESMO Congress 2019, Sep. 29, 2019, Barcelona, Spain. (Poster) [Abstract]
  14. Hiramoto S, Kikuchi A, Hori T, Yoshioka A, Nagashima K. Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life. ESMO World Congress on Gastrointestinal Cancer 2019, Jul. 3–6, 2019; Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
  15. Hiramoto S, Nagashima K, Hori T, Kikuchi A, Yoshioka A. Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy. ESMO World Congress on Gastrointestinal Cancer 2019, Jul. 3–6, 2019; Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
  16. Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. 2019 ASCO Annual Meeting, May 31–Jun. 4, 2019; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
  17. Hara H, Shoji H, Takahari D, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N, Kato K. Phase I/II study of ramucirumab plus nivolumab in patients in second line treatment for advanced gastric adenocarcinoma (NivoRam study). ASCO 2019 Gastrointestinal Cancers Symposium, Jan. 17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  18. Kumagai K, Yamaguchi T, Takashima A, Nagashima K, Kano Y, Terashima M, Yabusaki H, Nishikawa K, Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukunaga H, Kinoshita T, Watanabe M, Taniguchi H, Sakamoto T, Ishiyama K, Boku N. Comparison between S-1 monotherapy and S-1 plus cisplatin as post-operative chemotherapy after R0 resection for stage IV gastric cancer patients with oligo-metastasis: a multicenter retrospective study. ASCO 2019 Gastrointestinal Cancers Symposium, Jan. 17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  19. Ogasawara S, Ueshima K, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M. Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: a Japanese multi-center large cohort study. ASCO 2019 Gastrointestinal Cancers Symposium, Jan. 17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  20. Kita S, Takashima A, Hirano H, Aoki M, Imazeki H, Ishikawa M, Shoji H, Honma Y, Iwasa S, Okita N, Kato K, Nagashima K, Boku N. CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving second-line chemotherapy. ESMO Asia 2018 Congress, Nov. 24, 2018; Suntec Singapore Convention & Exhibition Centre, Singapore. [Abstract]
  21. Sato Y, Kobayashi T, Nishiumi S, Okaya S, Yoshida M, Kodama Y, Nagashima K, Honda K. Usefulness of the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic cancer and its risk diseases. ESMO 2018 Congress, Oct. 19–23, 2018; Messe Munich, Munich, Germany. [Abstract]
  22. Misawa S, Sato Y, Katayama K, Nagashima K, Sekiguchi Y, Amino H, Suichi T, Kuwabara S. The safety and efficacy of thalidomide treatment prior to autologous stem-cell transplantation in POEMS syndrome. 2018 Peripheral Nerve Society Annual Meeting, Jul. 21–25, 2018; Baltimore, Maryland. (Poster) [Abstract]
  23. Esaki T, Shoji H, Takahari D, Hara H, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N, Kato K. Preliminary result of p1/2 study of ramucirumab plus nivolumab in patients with pretreated advanced gastric carcinoma. 2018 the Japanese Society of Medical Oncology Annual Meeting, Jul. 19–21, 2018; Kobe Convention Center, Kobe. [Abstract]
  24. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide K, Ide S, Baba Y, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Takemoto M, Yokote K. Comparing the effects of ipragliflozin and metformin on visceral fat reduction in patients with type 2 diabetes inadequately controlled with sitagliptin–a prospective, multicenter, blinded-endpoint, randomized controlled study in Japan (PRIME-V study). American Diabetes Association, the 78th Scientific Sessions, Jun 22–26, 2018; Orange County Convention Center, Orlando, FL. [Abstract]
  25. Takahari D, Shoji H, Hara H, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N, Kato K. Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study). 2018 ASCO Annual Meeting, Jun 1–5, 2018; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
  26. Aizawa M, Yamaguchi T, Takashima A, Nagashima K, Ema A, Yuasa Y, Haruta S, Taniguchi H, Kobayashi D, Nishikawa K, Yunome G, Takagi M, Niwa H, Yamada T, Hato S, Fukagawa T, Boku N, Katai H. Comparison of S-1 and S-1 plus cisplatin as post-operative chemotherapy for gastric carcinoma with peritoneal lavage cytology positive or localized peritoneum metastasis: A multicenter retrospective study. ASCO 2018 Gastrointestinal Cancers Symposium, Jan. 18–20, 2018; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  27. Makuuchi R, Yamaguchi T, Takashima A, Nagashima K, Yamada T, Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hirabayashi N, Sakamoto T, Inada T, Ishiyama K, Fukagawa T, Boku N, Katai H. The impact of pre-operative chemotherapy in patients with peritoneal lavage cytology positive or localized peritoneum metastasis for gastric cancer: A multicenter retrospective study. ASCO 2018 Gastrointestinal Cancers Symposium, Jan. 18–20, 2018; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  28. Misawa S, Katayama K, Sato Y, Nagashima K, Sekiguchi Y, Suichi T, Amino H, Hanaoka H, Kuwabara S. Pre-transplant induction thalidomide treatment in poems syndrome: An open-labell phase II clinical trial. The XXIII World Congress of Neurology (WCN 2017), Sep 16–21, 2017; International Conference Center Kyoto, Kyoto. [Abstract]
  29. Suichi T, Misawa S, Nagashima K, Sekiguchi Y, Shibuya K, Watanabe K, Kuwabara S. Safety and efficacy of lenalidomide for intractable/recurrent poems syndrome: An open label pilot study. The XXIII World Congress of Neurology (WCN 2017), Sep 16–21, 2017; International Conference Center Kyoto, Kyoto. [Abstract]
  30. Shoji H, Miyamoto H, Hara H, Takahari D, Machida N, Esaki T, Nagashima K, Aoki K, Honda K, Nagata Y, Miyamoto T, Boku N, Kato K. A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma. ESMO 2017 Congress, Sep. 8–12, 2017; IFEMA - Feria de Madrid, Spain. (Poster)
  31. Sasaki Y, Kato K, Hirano H, Shoji H, Honma Y, Iwasa S, Takashima A, Hamaguchi T, Nagashima K, Boku N. Evaluation of α-1-acid glycoprotein as a prognostic marker and as a predictive biomarker for severe neutropenia induced by docetaxel in esophageal carcinoma patients. AACR Annual Meeting 2017; Apr. 1–5, 2017; Walter E. Washington Convention Center, Washington, D. C. (Poster) [Abstract]
  32. Terazawa T, Iwasa S, Sasaki Y, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T. A multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with advanced gastric cancer. ASCO 2017 Gastrointestinal Cancers Symposium, Jan. 19–21, 2017; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  33. Tsushita N, Honma Y, Nagashima K, Miyamoto T, Nakamura S, Umezawa R, Ito Y, Shoji H, Takashima A, Iwasa S, Kato K, Hamaguchi T, Itami J, Boku N. Risk factor analyses of severe cicatricial stricture after chemoradiotherapy for stage II/III (T3) esophageal carcinoma. ASCO 2017 Gastrointestinal Cancers Symposium, Jan. 19–21, 2017; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  34. Kato K, Kojima T, Ito Y, Igaki H, Daiko H, Onozawa M, Hamamoto Y, Matsushita N, Nagashima K, Katano S. Feasibility study of neo-chemoradiotherapy for stage IB/II/III esophageal squamous cell carcinoma: A 4-year follow up. 2016 the Japanese Society of Medical Oncology Annual Meeting, Jul. 28–30, 2016; Kobe Internatinal Conference Center & Kobe Internatinal Exhibition Hall, Kobe. [Abstract]
  35. Suzuki W, Ohyanagi F, Yanai T, Hashimoto H, Takashima A, Nakao M, Nakayama T, Iwasa S, Nagashima K, Yamamoto N. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by cisplatin-based chemotherapy. 2016 the Japanese Society of Medical Oncology Annual Meeting, Jul. 28–30, 2016; Kobe Internatinal Conference Center & Kobe Internatinal Exhibition Hall, Kobe.
  36. Hashimoto H, Yanai T, Nagashima K, Okita NT, Horinouchi H, Takiguchi T, Ohyanagi F, Nakao M, Takeda K, Nakayama T, Sakai H, Arai T, Minato K, Kogure Y, Harada D, Suzuki K, Boku N, Shimada Y, Iwasa S, Yamamoto N. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. 2016 ASCO Annual Meeting, Jun 3–7, 2016; McCormick Place, Chicago, Illinois. (Poster, J Clin Oncol 2016; 34(suppl): abstr 10111) [Abstract] HOT
  37. Ohba A, Takashima A, Nishiuchi T, Honma Y, Iwasa S, Okita N, Kato K, Hamaguchi T, Nagashima K, Boku N. Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. ASCO 2016 Gastrointestinal Cancers Symposium, Jan. 21–23, 2016; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  38. Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Yoshitaka Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Narikazu Boku N, Hamaguchi T, Heike Y. Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy. 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), Nov. 4–8, 2015; Gaylord National Hotel & Convention Center, National Harbor, Maryland. (Poster) [Abstract]
  39. Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Nagashima K, Okita N, Yamada Y. Impact of KRAS/NRAS mutation status on the outcomes of patients with stage III colorectal cancer: Correlative study in NSAS-CC/RC. The 18th ECCO - 40th ESMO European Cancer Congress, Sep. 25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
  40. Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Ito A, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Boku N, Hamaguchi T. Association between the peripheral immune status of granulocytic myeloid-derived suppressor cells and progression-free survival chemotherapy. The 18th ECCO - 40th ESMO European Cancer Congress, Sep. 25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
  41. Tada K, Shoji H, Kitano S, Nishimura T, Shimada Y, Nagashima K, Ito A, Honma Y, Iwasa S, Okita M, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy. The 18th ECCO - 40th ESMO European Cancer Congress, Sep. 25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
  42. Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Okita NT, Takashima A, Iwasa S, Kato K, Hamaguchi T, Shimada Y, Boku N, Yamada Y. Imaging peritoneal metastasis of gastric cancer with PET/CT and the radiotracer 18F-fluorothymidine (18F-FLT): Proof-of-concept study. 2015 ASCO Annual Meeting, May 29–Jun. 2, 2015; McCormick Place, Chicago, Illinois. (Poster discussion session) [Abstract]
  43. Hirashima Y, Hanaoka T, Watanabe K, Nagashima K, Inagaki T, Nishikawa K, Hisamatsu Y, Morinaga R, Otsu S, Kumamoto T, Shirao K. A prospective study to evaluate the usefulness of the clanging tuning fork test and the nerve conduction velocity test for oxaliplatin-induced peripheral neuropathy. ASCO 2015 Gastrointestinal Cancers Symposium, Jan. 15–17, 2015; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  44. Yuda S, Kato K, Sasaki Y, Takahashi N, Shoji H, Takashima A, Okita NT, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Nagashima K, Boku N. Risks of severe adverse events of docetaxel, cisplatin, and 5-fluorouracil (DCF) combination chemotherapy of esophageal cancer. ASCO 2015 Gastrointestinal Cancers Symposium, Jan. 15–17, 2015; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  45. Kubo A, Yamada Y, Takahashi N, Nagashima K, Hashimoto H, Iwasa S, Honma Y, Okita N, Takashima A, Kato K, Hamaguchi T, Hayashi Y, Shimada Y. Serum epiregulin is associated with prognosis and skin toxicity on anti-EGFR antibody treatment in KRAS wild-type mCRC. The 73rd Annual Meeting of the Japanese Cancer Association, Sep. 25–27, 2014; Pacifico Yokohama, Kanagawa. (Poster)
  46. Kubo E, Kato K, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Nagashima K. Comparison of the long-term toxicities with two different chemoradiotherapy for esophageal squamous cell carcinoma. The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 17–19, 2014; Fukuoka.
  47. Takahashi S, Ishiwada N, Hishiki H, Nagasawa K, Chang B, Nagashima K. Serotype distribution and drug resistance of streptococcuspneumoniae isolated from children with community acquired pneumonia in Japan. 13th International Congress on Pediatric Pulmonology, Jun. 26–29, 2014; Bruges, Belgium. (Poster) [Abstract]
  48. Iwasa S, Hamaguchi T, Nagashima K, Goto M, Okazaki S, Sasaki Y, Nagai Y, Asami C, Shimada Y. Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with advanced gastric cancer. ESMO 16th World Congress on Gastrointestinal Cancer, Jun. 25–28, 2014; Barcelona, Spain. (Poster) [Abstract]
  49. Kato K, Hashimoto J, Ito Y, Nagashima K, Kojima T, Daiko H, Akimoto T, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Igaki H. Phase II study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma: A 2-year follow up. ASCO 2014 Gastrointestinal Cancers Symposium, Jan. 16–18, 2014; The Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  50. Goto A, Yamada Y, Iwasa S, Nagashima K, Yamaguchi T, Ichikawa Y, Yasui H, Kato K, Okita NT, Shimada Y. S-1 and irinotecan versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: A pooled analysis of 4 phase II studies. The 17th ECCO, 38th ESMO, 32nd ESTRO, European Cancer Congress. Sep. 27–Oct. 1, 2013; Amsterdam. (Poster) [Abstract]
  51. Hirashima Y, Hanaoka T, Watanabe K, Nagashima K, Nishikawa K, Morinaga R, Otsu S, Kumamoto T, Shirao K. A prospective study to evaluate the usefulness of neurological test for oxaliplatin-induced peripheral neuropathy. The 11th Annual Meeting of Japanese Society of Medical Oncology, Aug. 29–31, 2013; Tohoku University Centennial Hall, Sendai, Miyagi.
  52. Kato K, Nakajima T, Ito Y, Katada C, Ishiyama H, Tokunaga S, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K, Nagashima K, Ishikura S. Phase II study of concurrent chemoradiotherapy with elective nodal irradiation for stage II-III esophageal carcinoma, modified RTOG regimen. The 9th Annual Meeting of Japanese Society of Medical Oncology, Jul. 21–23, 2011; Pacifico Yokohama, Yokohama, Kanagawa.
  53. Okita NT, Kato K, Tokunaga S, Esaki T, Baba E, Takiuchi H, Mizunuma N, Kato T, Inaba Y, Kanemitsu Y, Yasui H, Fuse N, Hamaguchi T, Yamada Y, Shimada Y, Nagashima K. Dose Initial tumor size affect bevacizumab efficay in 1st-line FOLFOX treatment for metastatic CRC? The 9th Annual Meeting of the Japanese Society of Medical Oncology, Jul. 21–23, 2011; Pacifico Yokohama, Yokohama, Kanagawa. (Poster)
  54. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada Y, Shirao K. New analysis of the hypertension mechanism in bevacizumab-treated patients using 3-Tesla dynamic contrast-enhanced magnetic resonance imaging. ASCO 2011 Gastrointestinal Cancers Symposium, Jan. 20–22, 2011; The Moscone West Building, San Francisco, CA. (Poster) [Abstract]
  55. Akiyoshi K, Yamada Y, Hirashima Y, Horita Y, Kato K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada Y. Phase II trial of the second-line 5-fluorouracil ℓ-leucovorin/irinotecan (FOLFIRI) and bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. ASCO 2010 Gastrointestinal Cancers Symposium, Jan. 22–24, 2010; The Orlando World Center Marriott, Orlando, Florida. (Poster)
  56. Yoshida H, Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. Phase II study of the "stop and go" modified FOLFOX6 regimen with bevacizumab for first-line patients with metastatic colorectal cancer. ASCO 2010 Gastrointestinal Cancers Symposium, Jan. 22–24, 2010; The Orlando World Center Marriott, Orlando, Florida. (Poster)

国内学会発表

    統計手法

  1. 長島健悟, 野間久史. 変量効果モデルによるメタアナリシスの予測区間. 統計関連学会連合大会, 2018年9月13日, 中央大学. [Slide]
  2. 長島健悟. Information criteria for Firth's penalized partial likelihood approach in Cox regression models. 統計数理研究所リスク解析戦略研究センター 第9回 生物統計ネットワークシンポジウム, 2018年3月19日, FUKURACIA 丸の内オアゾ. [Slide]
  3. 佐藤泰憲, 長島健悟. 個別化医療のための研究デザイン ～Enrichment Designを中心に～. 日本計算機統計学会 第27回大会, 2013年5月16日, 弘前大学創立50周年記念会館.
  4. 長島健悟. ゲノム網羅的解析における薬物動態関連遺伝子検出のためのスチューデント化修正最大対比法の提案. 統計数理研究所リスク解析戦略研究センター研究会, 2010年3月26日, 癌研究所. [Slide]
  5. 長島健悟, 佐藤泰憲, Laird NM. ゲノムワイド関連解析における薬物動態関連遺伝子同定のための新しいスクリーニング法. SASユーザー総会, 2009年7月30日, タワーホール船堀. [Report]
  6. 長島健悟, 堀尾浩史, 浜田知久馬. HWD 下での Fisher の正確検定の性能比較. 統計関連学会連合大会, 2007年9月7日, 神戸大学.

    7. 統計ソフトウェア

  7. 長島健悟. Rパッケージの開発・登録とメンテナンス. 2010年度 統計数理研究所共同研究集会「データ解析環境 R の整備と利用」, 2010年11月25日–27日, 統計数理研究所. [Slide]
  8. 長島健悟, 佐藤泰憲. Kaplan-Meier プロットに付加情報を追加するマクロの作成. SAS ユーザー総会, 2010年7月26日–27日, タワーホール船堀. [Report] [Slide]

    9. 共同研究 (臨床試験・疫学・基礎)

  9. 高橋直樹, 庄司広和, 高張大亮, 原浩樹, 江崎泰斗, 町田望, 長島健悟, 青木一教, 本田一文, 宮本敬大, 朴成和, 加藤健. NIVORAM試験におけるニボルマブ・ラムシルマブ併用療法の有効性とTMLとの関連性. 第92回日本胃癌学会総会, 2020年3月6日, パシフィコ横浜, 神奈川.
  10. 本田一文, 小林隆, 小西宏, 長島健悟, 吉田優. 血液バイオマーカーによる効率的な膵がん検診法とリスク層別化の可能性. 第78回日本癌学会学術総会, 2019年9月28日, 国立京都国際会館, 京都.
  11. 石川耕, 越坂理也, 石橋亮一, 前澤善朗, 坂本憲一, 内田大学, 中村晋, 山賀政弥, 横尾英孝, 大西俊一郎, 小林一貴, 荻野淳, 橋本尚武, 徳山宏丈, 大原恵美, 石川崇広, 正司真弓, 井出真太郎, 井出佳奈, 小林明菜, 馬場雄介, 高橋翔, 長島健悟, 佐藤泰憲, 竹本稔, 横手幸太郎. メトホルミンを対照としてイプラグリフロジンによる内臓脂肪面積の変化を検討した多施設共同無作為化比較試験PRIME-V Study. 第61回日本糖尿病学会年次学術集会, 2018年5月24日–5月26日, 東京国際フォーラム, 東京.
  12. 中山季昭, 酒井洋, 矢内貴子, 橋本浩伸, 後藤悌, 瀧口友美, 大柳文義, 中尾將彦, 武田晃司, 新井隆広, 湊浩一, 鈴木賢一, 岩佐悟, 長島健悟, 山本昇. 制吐作用を目的としたオランザピン10mgと5mgの有効性と安全性を評価する用量設定試験. 第54回日本癌治療学会学術集会, 2016年10月20日–10月22日, パシフィコ横浜, 神奈川.
  13. 中尾將彦, 吉田徹也, 矢内貴子, 橋本浩伸, 本永正矩, 瀧口友美, 大柳文義, 中山季昭, 齊藤こずも, 藤田行代志, 湊浩一, 鈴木賢一, 寺門浩之, 岩佐悟, 長島健悟, 山本昇. 高度催吐性化学療法施行時の悪心・嘔吐の予防に対するオランザピン10mgと5mgの有効性と安全性を評価する用量設定第2相試験. 第26回 日本医療薬学会年会, 2016年9月17日–9月19日, 国立京都国際会館・グランドプリンスホテル京都, 京都.
  14. 岩佐悟, 濱口哲弥, 後藤昌弘, 岡崎俊介, 笹木有佑, 長井祐志, 浅見千佳, 長島健悟, 島田安博. 高齢者切除不能の進行・再発胃癌を対象としたS-1/CDDP療法の多施設共同第Ⅱ相試験. 第52回 日本癌治療学会学術集会, 2014年8月28日–8月30日, パシフィコ横浜, 神奈川.
  15. 岩佐悟, 濱口哲弥, 後藤昌弘, 富所隆, 笹木有佑, 長井祐志, 浅見千佳, 長島健悟, 島田安博. 高齢者切除不能進行・再発胃癌を対象としたS-1/CDDP療法の多施設共同第II相試験. 第51回 日本癌治療学会学術集会, 2013年10月24日–10月26日, 国立京都国際会館・グランドプリンスホテル京都, 京都.
  16. 山口達郎, 山田康秀, 岩佐悟, 松本寛, 市川靖史, 後藤歩, 安井久晃, 加藤健, 沖田南都子, 長島健悟, 島田安博. 進行・再発大腸がんのS-1/イリノテカン±ベバシズマブ療法 第II相試験の統合解析. 第51回 日本癌治療学会学術集会, 2013年10月24日–10月26日, 国立京都国際会館・グランドプリンスホテル京都, 京都.
  17. 竜野真維, 加藤健, 本間義崇, 岩佐悟, 濱口哲弥, 山田康秀, 島田安博, 馬屋原博, 伊藤芳紀, 伊丹純, 長島健悟. 臨床病期 II/III 期食道がんに対する化学放射線療法における追加化学療法の意義について. 第66回日本食道学会学術集会, 2012年6月21日–6月21日, 軽井沢プリンスホテルウエスト, 長野.
  18. 中谷祥恵, 長島健悟, 増井彩乃, 川口光朗, 又平芳春, 藤堂浩明, 杉林堅次, 古旗賢二, 和田政裕. N-アセチルグルコサミンの摂取は健常人の季節変動に伴う肌水分量の低下を抑制する. 第25回キチン・キトサンシンポジウム, 2011年8月30日–31日, 奈良県新公会堂, 奈良.
  19. 徳永伸也, 沖田南都子, 江崎泰斗, 馬場英司, 坂井大介, 瀧内比呂也, 水沼信之, 長島健悟, 濱口哲弥, 加藤健. 切除不能進行・再発大腸がんに対する mFOLFOX6+BV stop and go 臨床第II相試験. 第8回日本臨床腫瘍学会学術集会, 2010年3月18日–3月19日, 東京ビッグサイト, 東京.
  20. 堀田洋介, 山田康秀, 加藤健, 平島詳典, 秋吉宏平, 長島健悟, 中島貴子, 濱口哲弥, 島田安博. 切除不能大腸癌二次治療例に対する FOLFIRI + Bevacizumab 療法の臨床第 2 相試験 (AVASIRI study). 第8回日本臨床腫瘍学会学術集会, 2010年3月18日–3月19日, 東京ビッグサイト, 東京. (Poster)
  21. 佐藤真樹, 上田秀雄, 長島健悟, 木村聡一郎, 寺尾哲, 青木富雄, 森本雍憲. 悪性腫瘍患者における感染性と非感染性発熱の識別モデルに関する検討. 日本薬学会 第129年会, 2009年3月26日–28日, グランドプリンスホテル京都, 京都市, 京都. (Poster)
  22. 橋本堅治, 高島淳生, 長島健悟, 佐藤宏征, 岡崎俊介, 中島貴子, 加藤健, 濱口哲哉, 山田康秀, 島田安博. 切除不能・再発進行胃がんに対する二次化学療法における予後因子の検討. 第46回 日本癌治療学会総会, 2008年10月30日–11月1日, 名古屋国際会議場, 名古屋.

その他の関連情報

Journal Reviewer

所属学会

委員等

研究領域

学歴

職歴

連絡先

E-mail:

Last updated date